PASG News and Press, Passage Bio Inc. From 08/04/21

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief ...

PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webc...

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced it has granted an inducement award to the c...

PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced three key leadership appointments. These exp...

dinn/iStock via Getty Images Passage Bio (PASG) is trading ~3.4% higher in the post-market after Raymond James started the coverage of the stock with an overweight rating and a price target of $29.00 per share to imply a premium of ~119.0% to the close. Passage Bio, described by the...

Passage Bio has failed considerably since I last covered it. They have also started or are about to start three trials. However, without data, there's no way to come to an investment decision. For further details see: Passage Bio: Price Reduced, But Without Data, Does No...

PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the election of Derrell D. Porter, M.D., to...

PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming v...

Passage Bio (PASG) lost ~17.9% today as the company is expected to lose two senior executives within a few days. The search for replacements has already begun.Yesterday after the market close, Passage Bio submitted a regulatory filing to inform that its chief financial officer Richard S. Morr...

Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy for metachromatic leukodystrophy (MLD) Passage Bio gene therapy candi...